Vinci Pharmaceuticals

Innovative, minimally invasive retinal disease pharmaceutic...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Vinci Pharmaceuticals, Inc.:
Fast Facts

Vinci Pharmaceuticals is a specialty ophthalmic pharmaceutical company focused on developing products with differentiated profiles for unmet medical needs of the retina. Treating retinal diseases with minimally invasive technology and sustained drug release.

Retinal diseases need better treatment options

There is a limited focus in ophthalmology on intermediate-stage therapeutics for retinal diseases that are safe, durable and minimally invasive. 

Dry Age-related Macular Degeneration (dAMD): No approved RX treatments

  • Largest unmet medical need in ophthalmology
  • Intermediate Dry AMD represents 50-60% of AMD
  • Need to slow disease progression with a non-invasive treatment

Our Solution

Vinci Pharmaceuticals is a specialty pharmaceutical company in the pre-clinical stage of developing treatments that will help prevent blindness for many millions of people suffering from intermediate stage diseases of the retina.

The Vinci solution is a powerful combination of our proprietary episcleral sustained-release implant and novel active pharmaceutical ingredients designed to be affordable.

Key Features

Delivering treatment where it’s needed
The Vinci solution utilizes a novel, proprietary platform with a unique implant technology delivering drugs to target tissues in the retina for positive clinical outcomes.

The right prescription at the right time
The active pharmaceutical ingredients are small molecules utilizing local ocular delivery. The treatment targets inflammation and alternative pathologic pathways for DME and targets dysfunctional mitochondria for dAMD.

  • For DME: a non-steroidal anti-inflammatory drug (NSAID) delivered via an episcleral sustained-release delivery system
  • For dAMD: a modified NAC-derivative delivered via an episcleral sustained-release delivery system 

Easy for the patient, with lasting results
Our minimally invasive ocular treatment has the potential for sustained delivery and treatment lasting up to four months.

Traction &

Product Development:
Preclinical, seed stage

ORA, Inc.
Retina Foundation, SW

Meet The Team

Philip Gioia: CO-FOUNDER / CEO

  • CEO, Eye Therapies
  • Board Advisor, TearClear, Ocugen
  • Bausch & Lomb
  • Warburg Pincus

Karl Csaky, MD, PhD: CO-FOUNDER

  • Managing & Chief Medical Director, Retina Foundation of the Southwest
  • T. Boone Pickens Director, Molecular Ophthalmology Laboratories and Clinical Center of Innovation for Macular Degeneration
  • Scientific Advisory Board: Roche, Allergan, Johnson & Johnson, Genentech, Regeneron, Merck, Novartis        

Peter Milligan: CFO

  • CFO, Melinta Therapeutics 
  • CFO, G&W Laboratories
  • SVP, CFO, Exelis

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.